Leadership Changes at Agios and Moderna: Board Resignation and New Marketing Chief

David P. Schenkein, M.D., will resign from Agios Pharmaceuticals' Board of Directors, effective February 28, 20251 4.

Dr. Schenkein will also step down from his role on the Science and Technology Committee of Agios' Board1.

He will continue to serve as a strategic advisor to Agios, focusing on advancing the company's clinical development programs1 4.

Moderna has appointed Amy Mahery as its new chief marketing officer, a senior VP role2.

Mahery previously served as chief commercial officer at Roivant Sciences and spent 18 years at EMD Serono, Merck KGaA's U.S. pharma subsidiary2.

Moderna is taking a more cautious approach to its commercial strategy, aiming for 10 new approvals over the next three years2.

Moderna expects sales between $1.5 billion and $2.5 billion in 2025, down from previous forecasts2.

Agios Pharmaceuticals, focused on cellular metabolism to treat cancer and rare genetic diseases, has a market capitalization of $1.87 billion1.

The FDA has recently accepted Agios' supplemental New Drug Application for PYRUKYND® as a potential treatment for adults with thalassemia1.

Sources: